What one share of 4D Molecular Therapeutics holds
We are a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients.
4D Molecular Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.43 |
|---|---|
| Profit | −$2.78 |
| Capex (buildings and equipment) | −$0.00 |
| Free cash flow | −$2.42 |
| Cash and investments | $7.80 |
| Debt | $0.35 |
| Book value | $7.38 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$9.59 | $0.62 | −$7.76 | — | −$14.09 |
| 2020 | — | −$8.82 | $0.16 | −$8.07 | — | — |
| 2021 | — | −$2.57 | $0.33 | −$2.82 | — | $9.90 |
| 2022 | — | −$3.32 | $0.36 | −$3.04 | — | $7.09 |
| 2023 | — | −$2.58 | $0.07 | −$2.01 | — | $7.15 |
| 2024 | — | −$2.98 | $0.07 | −$2.57 | — | $11.15 |
| 2025 | $1.47 | −$2.42 | $0.01 | −$1.89 | — | $8.78 |
Common questions about 4D Molecular Therapeutics
How much does one share of 4D Molecular Therapeutics earn?
Over the last 12 months, 4D Molecular Therapeutics lost $2.78 for each share on $1.43 of sales.
Does 4D Molecular Therapeutics pay a dividend?
4D Molecular Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is 4D Molecular Therapeutics’s book value per share?
4D Molecular Therapeutics’s book value is $7.38 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of 4D Molecular Therapeutics have?
Each share of 4D Molecular Therapeutics has $7.80 of cash and investments and $0.35 of debt, as of June 30, 2026.
What is 4D Molecular Therapeutics’s free cash flow per share?
−$2.42 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has 4D Molecular Therapeutics bought back shares?
4D Molecular Therapeutics’s share count rose about 1026% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.